NCT05542940

Brief Summary

Objective: Calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading. Patients and methods: 100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading. Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2022

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 8, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 16, 2022

Completed
Last Updated

September 16, 2022

Status Verified

September 1, 2022

Enrollment Period

2.7 years

First QC Date

September 8, 2022

Last Update Submit

September 13, 2022

Conditions

Endometrial Cancer

Outcome Measures

Primary Outcomes (4)

  • p53 immunohistochemistry

    Incidence of abnormal staining of p53 in endometrial cancer

    1 month

  • Relation of p53 abnormal staining with disease stages

    Relation of p53 abnormal staining with disease stages

    1month

  • Relation of p53 abnormal staining with disease pathological types

    Relation of p53 abnormal staining with disease pathological types

    1 month

  • Relation of p53 abnormal staining with disease pathological grades

    Relation of p53 abnormal staining with disease pathological grades

    1 month

Interventions

p 53 immunohistochemistry positive staining and relation to stages ,pathological types and gradingOTHER

p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading

Eligibility Criteria

Sexfemale
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

randomized

You may qualify if:

  • endometrial cancer patients

You may not qualify if:

  • patients unfit for surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hossam Hassan El Sokkary

Alexandria, Egypt

Location

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

September 8, 2022

First Posted

September 16, 2022

Study Start

January 1, 2020

Primary Completion

August 31, 2022

Study Completion

August 31, 2022

Last Updated

September 16, 2022

Record last verified: 2022-09

Locations

EG(1)